The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Activity of Dabrafenib/Trametinib Combo in Patients With Melanoma Brain Metastases

Georgina V. Long, BSc, PhD, MBBS
Published Online:6:10 PM, Mon June 19, 2017

Georgina V. Long, BSc, PhD, MBBS, professor of medical melanoma oncology, Melanoma Institute Australia, discusses the activity seen with the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) for the treatment of patients with melanoma brain metastases.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.